Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter

被引：6
作者：
Businello, Gianluca [1 ]
Angerilli, Valentina [1 ]
Lonardi, Sara [2 ]
Bergamo, Francesca [2 ]
Valmasoni, Michele [3 ]
Farinati, Fabio [3 ]
Savarino, Edoardo [3 ]
Spolverato, Gaya [3 ]
Fassan, Matteo [1 ,2 ]
机构：
[1] Univ Padua, Dept Med DIMED, Padua, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Veneto Inst Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
来源：
UPDATES IN SURGERY | 2023年 / 75卷 / 02期
关键词：
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Biomarkers; Immunohistochemistry; ADVANCED GASTRIC-CANCER; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; HER2; STATUS; PHASE-II; MICROSATELLITE INSTABILITY; GASTROESOPHAGEAL CANCER;
D O I：
10.1007/s13304-022-01330-5
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
引用
收藏
页码：291 / 303
页数：13
相关论文
共 50 条
  • [31] Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
    Kubota, Y.
    Kawazoe, A.
    Mishima, S.
    Nakamura, Y.
    Kotani, D.
    Kuboki, Y.
    Bando, H.
    Kojima, T.
    Doi, T.
    Yoshino, T.
    Kuwata, T.
    Shitara, K.
    ESMO OPEN, 2023, 8 (01)
  • [32] Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
    Catenacci, Daniel V.
    Chao, Joseph
    Muro, Kei
    Al-Batran, Salah Eddin
    Klempner, Samuel J.
    Wainberg, Zev A.
    Shah, Manish A.
    Rha, Sun Young
    Ohtsu, Atsushi
    Liepa, Astra M.
    Knoderer, Holly
    Chatterjee, Anindya
    Van Cutsem, Eric
    ONCOLOGIST, 2021, 26 (10) : E1704 - E1729
  • [33] Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
    Yuan, Zhen
    Cui, Hao
    Wang, Shuyuan
    Liang, Wenquan
    Cao, Bo
    Song, Liqiang
    Liu, Guibin
    Huang, Jun
    Chen, Lin
    Wei, Bo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
    Wood, Anthony C.
    Zhang, Yonghong
    Mo, Qianxing
    Cen, Ling
    Fontaine, Jacques
    Hoffe, Sarah E.
    Frakes, Jessica
    Dineen, Sean P.
    Pimiento, Jose M.
    Walko, Christine M.
    Mehta, Rutika
    ONCOLOGIST, 2022, 27 (04) : 307 - 313
  • [35] Gastric HER2 Testing Study (GaTHER): An Evaluation of Gastric/Gastroesophageal Junction Cancer Testing Accuracy in Australia
    Fox, Stephen B.
    Kumarasinghe, Marian Priyanthi
    Armes, Jane E.
    Bilous, Michael
    Cummings, Margaret C.
    Farshid, Gelareh
    Fitzpatrick, Nicole
    Francis, Glenn D.
    McCloud, Philip I.
    Raymond, Wendy
    Morey, Adrienne
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (04) : 577 - 582
  • [36] Prognostic nutritional index in predicting survival of patients with gastric or gastroesophageal junction adenocarcinoma: A systematic review
    Fiflis, Stylianos
    Christodoulidis, Grigorios
    Papakonstantinou, Menelaos
    Giakoustidis, Alexandros
    Koukias, Stergos
    Roussos, Paraskevi
    Kouliou, Marina Nektaria
    Koumarelas, Konstantinos Eleftherios
    Giakoustidis, Dimitrios
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (02) : 514 - 526
  • [37] Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study
    Plum, Patrick S. S.
    Barutcu, Atakan G. G.
    Pamuk, Aylin
    Mallmann, Christoph
    Chon, Seung-Hun
    Chiapponi, Costanza
    Duebbers, Martin
    Hellmich, Martin
    Moenig, Stefan P. P.
    Quaas, Alexander
    Hoelscher, Arnulf H. H.
    Bruns, Christiane J. J.
    Alakus, Hakan
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (08) : 2324 - 2333
  • [38] MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
    Catenacci, Daniel V. T.
    Rosales, Minori
    Chung, Hyun Cheol
    Yoon, Harry H.
    Shen, Lin
    Moehler, Markus
    Kang, Yoon-Koo
    FUTURE ONCOLOGY, 2021, 17 (10) : 1155 - 1164
  • [39] The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
    Brar, Gagandeep
    Shah, Manish A.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [40] Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    Tian, Yuan
    Zhao, Qun
    Li, Yong
    Fan, Liqiao
    Zhang, Zhidong
    Zhao, Xuefeng
    Tan, Bibo
    Wang, Dong
    Yang, Peigang
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
12345